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In adults, physiological angiogenesis is a rare event, with few exceptions as the vasculogenesis needed for tissue growth and
function in female reproductive organs. Particularly in the corpus luteum (CL), regulation of angiogenic process seems to be tightly
controlled by opposite actions resultant from the balance between pro- and antiangiogenic factors. It is the extremely rapid sequence
of events that determines the dramatic changes on vascular and nonvascular structures, qualifying the CL as a great model for
angiogenesis studies. Using the mare CL as a model, reports on locally produced cytokines, such as tumor necrosis factor 𝛼 (TNF),
interferon gamma (IFNG), or Fas ligand (FASL), pointed out their role on angiogenic activity modulation throughout the luteal
phase. Thus, the main purpose of this review is to highlight the interaction between immune, endothelial, and luteal steroidogenic
cells, regarding vascular dynamics/changes during establishment and regression of the equine CL.
1. Introduction
The angiogenic process plays an essential role during organo-
genesis and embryo development [1]. Angiogenesis itself can
be classified as the process of new blood vessels formation
from the preexisting vasculature. In adult tissues angiogenesis
is very limited, and blood vessels remain quiescent until there
is an angiogenic stimulus, such as hypoxia or wounding [2].
Besides the essential role of angiogenesis on wound healing,
it also plays a major function in various diseases and tumori-
genesis [3]. In contrast, after puberty, tissue growth and
function of female reproductive organs (placenta, ovary, and
corpus luteum) under physiologic conditions are extremely
dependent on new blood vessels formation [4, 5].
Angiogenesis is a highly regulated process involving the
balance between pro- and antiangiogenic factors. Locally,
endothelial surrounding cells produce growth factors, cytok-
ines, enzymes, receptors, adhesion molecules, and metabolic
factors that regulate the angiogenic process. In this way,
interaction between immune and endothelial cells should not
be neglected [6]. It is well known that inflammatory cells,
namely, macrophages, T lymphocytes, and monocytes, fully
participate in the angiogenic process by secreting pro- and/or
anti-inflammatory cytokines, which may control endothelial
cells migration and activation, proliferation, survival, and
apoptosis [7]. With particular regard to the ovary, it is well
established that immune cells contribute for ovarian function
regulation [8]. Moreover, immune cells present in the corpus
luteum (CL) can be considered as a large pool of mobile cells
that putatively modulate luteal establishment, maintenance,
and regression. Overall, little is known about the complex
cross-talk between immune and vascular systems in the
CL. The plethora of intervenient cytokines and their often
pleiotropic range of actions demand our attention to better
understand luteal angiogenesis regulation.
This review focuses on themodulation of angiogenesis by
cytokines in the CL, addressing, in a chronological fashion,
the events occurring from the follicle to the regressing CL.
Special emphasis will be put on angiogenesis and cytokines
action in the mare CL, since this research team has been
gathering both descriptive and functional knowledge on
the expression and role of cytokines like tumor necrosis
factor alpha (TNF), interferon gamma (IFNG), Fas ligand
(FASL), vascular endothelial growth factor A (VEGF), and
nitric oxide (NO), among others, on equine luteal function.
Due to the particular similarities between woman and mare
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(monovulatory species) onmany aspects of ovarian function,
mare CL is a valuable study model for understanding the
regulatory pathways involved on the control of ovarian
physiology [9]. Besides, most physiologic studies on woman
ovarian function are based on the knowledge generated from
abnormal tissue or granulosa cells collected from in vitro
fertilization [10]. Therefore, their physiologic relevance is
questionable [10], being the mare ovary a better study model.
2. Angiogenesis in the Corpus Luteum: A
Chronological Sequence of Events from
the Follicle to the Regressed Corpus Luteum
Different studies indicate that the CL is one of the most vas-
cularized organs in the body [11, 12]. The CL undergoes
extremely rapid cellular and vascular changes, only compa-
rable with tumors [13]. The coordination of those biological
processes is the outcome of a complex cross-talk between
several factors. In the CL, as in other organs, angiogenesis
seems to be tightly controlled by stimulating and inhibiting
factors [14] that might regulate its vascularization and func-
tion [14, 15]. Development of the microvasculature during
luteal establishment and formation is required for the deliv-
ery of adequate levels of hormones and lipoprotein bound
cholesterol [16]. Quantitative reports in ruminants showed
that in early luteal phase CL (early CL) more than 85% of
proliferating cells are endothelial cells, while in mature CL
more than 50% [12].
2.1. Starting from the Follicular Vasculature. During follicular
growth, angiogenesis is determinant for preantral follicle
development, follicle dominance, and preovulatory develop-
ment [17]. Around 40% of proliferating cells in the theca are
of endothelial origin [18]. Moreover, the blood clot formed
during ovulation might stimulate cell migration. Indeed,
platelets are a better stimulant for endothelial cells migration
than granulosa cells themselves [19]. Examples of proangio-
genic cytokines acting on this stage of the cycle include the
cytokines fibroblast growth factor 2 (FGF2), VEGF, platelet-
derived growth factor (PDGF) family, and angiopoietin
(Ang). The VEGF has been described as the main proangio-
genic factor, which is also produced by luteal cells [13, 14]. In
fact, treatmentswith antiangiogenic compounds (VEGF trap)
impaired follicular development [20]. Definitely, VEGF plays
a central role, since its blockade abolished endothelial cell
proliferation, luteal vascularization, and progesterone (P4)
production in rat [21] and mouse CL [22].
In mares, dominant follicles show an increase in blood
flow prior to deviation, when compared with subordinated
follicles [23]. This follicular vascular bed provides the basis
on which luteal vasculature will be formed [24]. It has been
noticed that in the developing follicle granulosa and theca
cells produce proangiogenic factors [25]. At the time of
ovulation, the LH surge induces several important cellular
and biochemical changes [26]. Specifically, breakdown of the
basement membrane and immune-like responses are deter-
minant for angiogenesis promotion [27]. Breakdown and
reorganization of the blood vessel basement membrane
involve a plethora of proteases, including matrix metallopro-
teinase (MMP) family, such as collagenases, gelatinases, and
membrane-type MMP. Several MMPs (MMP9, MMP13, and
MT-MMP1), which are primarily secreted by macrophages
in the ovary of many species (reviewed by Wu et al. [28]),
are upregulated by the LH surge [29]. It should be noticed
that some of these MMPs also participate on the ovulatory
process [30].Thus, the physical block to vascularization of the
granulosa layer is removed, and breaking down and spreading
extracellular matrix (ECM) components take place, creating
a more spacious environment facilitatingmotility andmigra-
tion of endothelial cells and others. Another important con-
sequence is the release of angiogenic factors sequestered in
the basement membrane. Disintegrin and metalloproteinase
with a thrombospondin (TSP) type 1 motif (ADAMTS) are
proteases that appear to be critical for angiogenesis following
ovulation [31]. The ADAMTS1 cleaves the matrix proteo-
glycans, expressed in the periovulatory follicle. Besides,
ADAMTS1 is increased by gonadotropin stimulation [32],
possibly mediated by hypoxia-induced factor 1𝛼 (HIF1A)
pathway [33]. This might be important for endothelial cell
invasion, since it is upregulated when these cells invade the
collagen matrix, following VEGF and FGF2 stimulation [34].
Another important trigger for the increased blood flow is
the HIF1A, whose expression is upregulated in the collapsed
follicle of pigs [35], suggesting that this tissue is hypoxic. The
relationship between LH, VEGF, FGF2, and HIF1A is still
not clear for the period of follicular-luteal transition, but it
is possible that VEGF raise following LH surge is mediated
by HIF1A [36].
The cytokine TNF also presents an increased expression
at the ovulation time [37], suggesting its participation on the
ovulation process and incoming steps of luteal growth. Tumor
necrosis factor 𝛼 and its receptors presence was shown in the
early CL of cow [38], pig [39], human [40], and horse (further
discussed in detail) [41]. Regarding the TNF cellular action,
the type of receptor involved should be considered. Indeed,
TNF can induce both cell proliferation and death, depending
onwhich receptor it binds to (TNFRI, the proapoptotic recep-
tor; or TNFRII, the prosurvival receptor) [42, 43]. Reports
in bovine CL demonstrated the TNF mediates endothelial
cells proliferation [44–46]. Moreover, TNF participation in
early CL vascularization should be considered alongside with
the generation of NO. Studies by Okuda and coworkers evi-
denced that endothelial cells of bovine CL treated with TNF
exhibited an increase in NO secretion [47], confirming the
relevance of TNF/NO interaction on luteal angiogenesis in
cows. The NO is considered a vasoactive substance, respon-
sible for endothelial cells proliferation and VEGF secretion
[48]. As shown for the mare, the NO donor (spermine
NONOate) was able to stimulate angiogenic activity in early
CL [49]. In parallel, the expression of NO generating enzyme,
the endothelial NO synthase (eNOS), was increased in equine
early CL [49], supporting NO role on luteal angiogenesis
promotion.
Finally, as reviewed by Shirasuna and co-workers [50]
polymorphonuclear leukocytes (PMNs) invade the CL soon
after the ovulation. Neutrophils infiltration of bovine early
CL (days 1–4) was correlated with a high concentration of
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interleukin 8 (IL-8, a neutrophil chemoattractant specific fac-
tor), suggesting that this cytokine also promotes angiogenesis
in the CL [43, 44].
2.2. Luteal Endothelia Cell Migration and Proliferation.
Endothelial cell migration involves its polarization towards
an angiogenic stimulus, protrusion through filopodia-like
structures, traction, and then retraction [51]. It is recognized
that, in bovine CL, fibronectin forms a network of fibrils
orientated along the axis of the capillary sprout [52], acting
as a “prepatterned” guideline for endothelial cells migration.
Fibronectin showed also a stimulatory effect on luteal-
derived endothelial cell proliferation [53] and formation of
endothelial cell networks in vitro [24]. Still considering the
endothelial cell migration, it is believed that recently formed
steroidogenic luteal cells can secrete the chemoattractants
VEGF and FGF2, working on endothelial cells migration
towards themselves [24].
The FGF2 also appears to be critical to endothelial
network formation, since suppression of its receptor almost
completely inhibited angiogenesis, by decreasing both the
number of endothelial clusters and their size in the cow CL
[24]. This occurred even in the presence of VEGF, empha-
sizing the importance of FGF2. Moreover, FGF2 expression
increases during the initial stage of luteal formation, being a
far more effective promoter of endothelial cell proliferation
than VEGF [54]. It is suggested that both factors may
have complementary rather than redundant actions on luteal
angiogenesis [24].
Of particular interest for angiogenesis regulation in early
CL is the modulation of FGF2 expression by prostaglandin
(PG) F2𝛼. As recently reported for early CL in cows (day
4), the so-called luteolytic PGF2𝛼 strongly increased FGF2
expression (mRNA and protein) [55]. From this standpoint,
PGF2𝛼 would promote CL vascularization and support CL
growth. In order to justify PGF2𝛼 putative effect on CL estab-
lishment, it was also suggested that PGF2𝛼 is able to interact
with PGE
2
receptors, when present in high concentrations
[56]. Admittedly, the role of PGF2𝛼 on vascularization during
CL growth awaits further research. However, the present
evidence of PGF2𝛼 support onVEGF, FGF2, and P4 secretion
in bovineCL confirms its participation onCL growth [55, 57].
2.3. A Mature Vascular System in the Corpus Luteum. Endo-
thelial cells need structural support. Mural cells such as
pericytes vascular smooth muscular cells ensure the shape
and regulate blood flow through their contractile properties.
The final step of angiogenesis is the vessel stabilization,
achieved with the secretion of platelet-derived growth factor
beta (PDGFB), which acts on a paracrine fashion on pericytes
recruitment [58]. For many years the role of pericytes on
angiogenesis was neglected. However, there is growing evi-
dence of their importance on the promotion of angiogenesis
initiation. During the ovulation time, pericytes are located at
what appears to be the forefront of the endothelial migratory
path [59], whilst in mature CL they are closely associated
with endothelial cells. Furthermore, pericytes represent a
large number of proliferating cells in the early ovine CL
[59]. Firstly, pericytes act as guiding structures aiding the
outgrowth of endothelial cells.They produceMMPs andmay
promote endothelial cell invasion, by destroying ECM.Then,
pericytes are recruited for vessel stabilization [24]. Activation
of these cells was associated with the platelet-derived growth
factor (PDGF) system. Preovulatory treatment of mice with
soluble ectodomain of PDGF receptor (PDGFR) prevented
the recruitment of pericytes and reduced the staining of
vascular area in CL [22], while the in vitro inhibition of
PDGFR domain decreased the vascular network formation
in bovine CL [54].
2.4. Luteolysis Demands Vascular Regression. A fundamental
question concerning regression of the CL is whether regres-
sion of vasculature plays a role on functional and structural
luteolysis. It was reported in sheep [60] and guinea pig [61]
that apoptosis of endothelial cells presumably originated the
occlusion of blood vessels with cellular debris. This could
result in subsequent apoptosis of more endothelial cells
followed by apoptosis of steroidogenic cells [62]. A pitfall
determining the importance of endothelial cells apoptosis
on luteolysis may be the fact that the temporal association
between them diverges among species.The evidence in sheep
and cow that PGF2𝛼 induces apoptosis of endothelial cells,
resulting in a luteolytic cascade [63], is not that obvious in
primates [64]. Nonetheless, death of vascular cells undoubt-
edly leads to a reduction in oxygen supply and nutrients
to hormonal producing cells, perhaps contributing for their
death.
The main luteolytic agent, the uterine PGF2𝛼, has been
associated with in vivo changes on vasculature. In fact, it has
been proposed that the main consequence of PGF2𝛼 is the
decrease in luteal blood flow [65]. However, following PGF2𝛼
administration, different responses are seen among species.
In the cow, an acute increase on luteal blood flowwas verified
after 30 minutes to 2 h following administration of PGF2𝛼
[63]. A similar increase in blood flow at the beginning of
luteolysis was not confirmed for the mare [66], whose luteal
blood flow to the mid CL decreases some days before the
decline in plasma P4 [67]. Several studies have related luteal
blood flow changes seen in the cow with the potent vasore-
laxant NO. The NO mediated raise in blood flow in cows
accelerates neutrophils infiltration of theCL,mainly resulting
in the production of various inflammatory cytokines pro-
duction, such as IL-8, TNF, or INFG [68]. The IL1𝛽 was
also related with luteolysis via NO synthesis promotion [69].
Additionally, these factors may be determinant for further
luteal infiltration with immune cells (macrophages and T
lymphocytes), supporting luteolytic cascade. Still regarding
PGF2𝛼 effect on cellular changes during luteolysis, it was
hypothesized that pericytes may serve as a regulator of tissue
remodeling and integrity maintenance of large blood vessels,
allowing normal luteolysis to occur [70]. Intriguingly, the
pericytes, which are known to support angiogenesis [59],
appear to participate in vascular regression during luteolysis.
The involvement of NO in equine CL regulation, specif-
ically modulating changes in the vasculature, was recently
described [49]. As previously mentioned (prior Section 2.1),
eNOS protein was shown to be highly expressed in the mare
early CL, when NO stimulated luteal tissue for angiogenic
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factors production and induced bovine aortic endothelial
cells (BAEC) proliferation (used as a model to assess angio-
genic factors production by luteal cells). Expression of eNOS
was reduced in mid CL, and NO no longer increased BAEC
mitogenic activity. In addition, participation of NO in vascu-
lar changes regulation throughout the luteal phase should be
true also for the mare, since eNOS expression was increased
once again in late luteal phase CL (late CL) [49]. Thus, NO is
also involved in angioregulation during luteolysis.
The cytokines TNF and IFNG were shown to play a role
in bovine luteal endothelial cells regulation [71]. Moreover,
referred cytokines can interact with endothelin-1 (ET-1;
mainly produced by endothelial cells) and PGF2𝛼, inhibiting
luteal steroidogenesis [72]. Two prior reports evidenced that
TNF is cytotoxic for endothelial cells derived from bovine
CL [73, 74]. Likewise, IFNG has been suggested as a locally
secreted factor that may support TNF cytotoxic effect on
bovine luteal endothelial cells [16]. Furthermore, cytokines
TNF and IFNG can directly incite MCP-1 secretion and
contribute for apoptosis of endothelial cells [61]. The present
findings suggest that a cross-talk between immune and
endothelial cells accounts for the increase in MCP-1 level and
endothelial cell death, during PGF2𝛼-induced luteal regres-
sion [75].
Changes in PGs and blood flow are considered necessary
for local release of ET-1 and angiotensin II (ANGII), which
further induce vasoconstriction and blood flow reduction
[76]. Besides showing other biological functions, ET-1 is
considered a potent vasoconstrictor, by acting on its receptor
A [77]. Concerning the ANGII, it regulates several biological
processes besides angiogenesis, including vascular tone and
cellular growth. In cows, production of ANGII in the CL was
associated with renin-angiotensin system [78]. Both ET-1 and
ANGII can reduce luteal steroidogenesis and are considered
vasoactive factors determinant for the luteolytic pathway and
vascular regression [57].
Finally, vascular regression under the luteolytic context
can be considered as a component of structural luteolysis.
Generally, structural luteolysis implies strong ECM remod-
eling. As a result, MMPs participation is required once again
but this time towards angioregression. It was demonstrated
that, after PGF2𝛼 treatment, expression of MMPs (MMP1,
MMP2, and MMP9) was increased, and this effect was
potentiated by TNF [79]. Moreover, the same study showed
that tissue inhibitor of metalloproteinase 1 (TIMP1, a specific
inhibitor of matrix metalloproteinase) level was decreased
during PGF2𝛼-induced luteolysis, increasing the ratio of
MMPs/TIMPs [79].
3. Vascular Regulation in the Equine
Corpus Luteum
3.1. Angiogenic Function Characterization in the Equine CL.
Since considerable differences are seen in the histology of the
CL among species, the pattern of luteal vascularization should
diverge. So far, few studies have described angiogenesis
regulation in equine CL. Dynamic changes on vascular area
in themareCLwere described throughout the luteal phase for
the first time [15]. Amarked increase in vascular areawas seen
in both early andmid CL, even though the vessel number was
the highest inmid and late CL.The raise inDNA content seen
fromearly tomidCLwas associated not onlywith hyperplasia
and luteal cell proliferation but also with endothelial cells
proliferation [15]. Besides, the decrease in vascular area in
the late CL might have been associated with the decrease in
blood vessel lumen resultant from vessels contraction. This
decrease in capillary diameter is considered determinant for
blood flow fall and can initiate or accelerate luteal regression
[80].
Among the various factors involved in luteal angiogene-
sis, VEGF appears to be the most important one for equine
CL. It was evidenced that both VEGF mRNA transcription
and protein expression peak in early andmidCL [81]. A direct
temporal correlation with angiogenesis, blood vessels prolif-
eration, and capillary density was established [81]. Besides,
the presence in both follicular and luteal cells from equine
ovary of VEGF, VEGF B, Ang1, Ang2, and the receptors
VEGFR1, VEGFR2, and Tie2 was recently demonstrated
[82]. A different staining was seen for VEGF, VEGFR2, and
Ang2 in the periovulatory period (including the tertiary, the
Graafian follicles, and early CL) [82].These data showed their
participation on equine luteal angiogenesis initiation. The
Ang1 staining was mostly associated with arterioles, venules,
arteries, and veins, compared with capillaries, suggesting a
role on stabilization of this vasculature [83]. Regardless of
the luteal stage, VEGFR1 was associated with mild expres-
sion intensity, and the complex VEGFB/VEGFR1 was not
associated with proangiogenic events in the mare CL [82].
Furthermore, in the mature CL (mid CL) a more intense
staining of proangiogenic studied factors could be observed
specifically in the array of the vascular septa and in the CL
periphery. These findings are in agreement with those from
Al-zi’abi et al. [81]. In mid CL, capillary endothelial cells
showed a less intense staining, mainly regarding VEGFR2
and Tie2, when compared with early CL. Also, luteal cells
were characterized by a weaker immunolabeling for VEGFR2
in the mid CL [82].
3.2. Cytokines and Angiogenesis Regulation in the Equine CL
(i) Luteal Establishment. Our team described the role of
cytokines TNF, IFNG, and FASL on equine CL angiogenesis
regulation. It is important to indicate that the cytokine
TNF showed proangiogenic properties in early CL in the
mare, after (i) increasing endothelial cells BAEC viability,
(ii) increasingmRNA level of proangiogenic VEGF/VEGFR2
complex, and (iii) decreasing antiangiogenic CD36 (TSP1
receptor) [84] (Figure 1). Moreover, in mid CL treated cells,
TNF increased VEGF protein expression [84] (Figure 2).
By assessing BAEC viability, the ability of TNF to mod-
ulate angiogenesis by equine luteal cells was characterized
(Figure 1(a)). In our study, VEGF and its receptor VEGFR2
mRNA levels were increased by TNF in the early CL
(Figure 1(b)). Protein analysis also showed a stimulatory role
of TNF on VEGF expression by mid CL cells (Figure 2).
When the inhibitory effect of TNF on the mRNA level
of the antiangiogenic receptor CD36 in early CL cells is taken
into consideration, these findings suggest that TNF might
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Figure 1: Figure adapted and modified from Galvão et al. [84]. (a) Bovine aortic endothelial cell (BAEC) proliferation rate, after incubation
with conditionedmedia from luteal cells obtained from early CL (cytokines treatment for 24 h). (b) Relative quantification of VEGF, VEGFR2,
TSP1, and CD36 mRNA transcription by real time PCR in early CL luteal cells (cytokines treatment for 24 h). Transcription normalized with
the housekeeping gene—B2MG. Bars represent mean ± SEM. Asterisks indicate significant differences ( ∗𝑃 < 0.05; ∗∗∗𝑃 < 0.001), regarding
the control values.
























Figure 2: Figure adapted and modified from Galvão et al. [84]:
VEGF protein expression in equine mid CL. Upper panels depict
representative Western blot (𝑛 = 4). Lanes: (1) control; (2) TNF;
(3) IFNG; (4) FASL; and (5) TNF + IFNG + FASL. Data normalized
against𝛽-actin density values. Bars representmean± SEM.Asterisks
indicate significant differences ( ∗𝑃 < 0.05; ∗∗𝑃 < 0.01).
participate in angiogenesis at the time of luteal formation in
the mare.
In spite of not being the only factor involved in endothe-
lial cells promotion, VEGF is a crucial promoter of ovarian
angiogenesis [20]. Thus, the interaction between TNF and
VEGF may be determinant for luteal vasculature establish-
ment. For instance, VEGF, which is secreted by macrophages
in human ovary [28], was shown to be chemotactic for the
same immune cell type, inducing neovascularization in mice
[85]. Our group recently concluded that equine mid CL iso-
lated cells treated with VEGF presented a raise in TNF secre-
tion (Figure 3). This suggests the existence of a luteotrophic
intraluteal loop, where TNF increases the VEGF production
by equine luteal cells, and, in turn, VEGF synergically acts
























Figure 3: VEGF and LH action on TNF production bymid CL cells,
after a 24 h stimulation. Stimulation dose for VEGF 50 ng/mL and
for LH 10 ng/mL. Bars represent mean ± SEM. Asterisks indicate
significant differences ( ∗∗𝑃 < 0.01; ∗∗∗𝑃 < 0.001). Luteal tissue
and venous blood from jugular vein were collected after mortem at
the local abattoir from randomly designated cyclic Lusitano mares.
The luteal structures were classified in different luteal stages (early,
mid, and lateCL) as previously described [72, 82]. Allmethodologies
for luteal cells isolation and culture, culture medium analysis by
enzymatic immuno assay, and statistical analysis were recently
described in detail [72].
on TNF secretion. The notorious interaction between both
immune and vascular systems here characterized is in
agreement with previous findings in bovine CL [86]. Still
considering the TNF/VEGF loop, the LH action should also
be discussed. We demonstrated that mid CL LH treated
cells presented an increase in TNF output, compared with
control (Figure 3). As a matter of fact, LH is a major regulator
of angiogenesis in several species [27], but its exact effect
conducting luteal vascularization is not known. The in vitro
stimulatory effect of LH on VEGF secretion by granulosa

















































































































Figure 4: Schematic proposed interaction between endothelial, immune, and steroidogenic luteal cells in equine CL: (a) in early CL LH
triggered luteotrophic loop betweenTNF,VEGF, and other factors during luteal growth; (b) in lateCLPGF2𝛼 triggered luteolytic loop between
cytokines FASL and cytokines synergic action TNF + IFNG + FASL towards angioregression and luteolytic cascade. Thick arrows indicate
synergistic action of cytokines TNF + IFNG + FASL. The symbol + means increase in transcription/translation level; the symbol—means
decrease in transcription/translation level. LH: luteotrophic hormone; LHR: LH receptor; PG: prostaglandin; PTGF: PGF2𝛼 receptor; P4:
progesterone; TNF: tumor necrosis factor 𝛼; TNFR: TNF receptor; IFNG: interferon gamma; IFNR: IFNG receptor; FASL: Fas ligand; FAS:
FASL receptor; FGF2: fibroblast growth factor 2; FGFR: FGF2 receptor; VEGF: vascular endothelial factor A; VEGFR2: VEGF receptor 2.
cells has been described in cows [86] and women [87]. In
view of the present data, one may suggest that LH triggers
TNF production during equine luteal angiogenesis promo-
tion (Figure 4(a)), acting on different cellular departments,
such as luteal cells, immune cells, or endothelial cells. As a
result, TNF auto-, paracrine action (mainly on endothelial
cells) stimulates VEGF production. The stimulus for vessels
proliferation is then maintained with the VEGF action on
luteal steroidogenic cells, via TNF transcription activation
and transduction. Furthermore, TNF is a potent leukocyte
chemoattractant factor, increasing this way the immune
cells population in the developing CL (T cells, neutrophils,
Mediators of Inflammation 7






















































Figure 5: Figure adapted and modified from Galvão et al. [84]. (a) Bovine aortic endothelial cell (BAEC) proliferation rate, after incubation
with conditioned media from luteal cells obtained from late CL (cytokines treatment for 24 h). (b) Relative quantification of VEGF, VEGFR2,
TSP1, and CD36 mRNA transcription by real time PCR in late CL luteal cells (cytokines treatment for 24 h). Transcription normalized with
the housekeeping gene—B2MG. Bars represent mean ± SEM. Asterisks indicate significant differences ( ∗𝑃 < 0.05; ∗∗∗𝑃 < 0.01), regarding
the control values.
eosinophils, and macrophages are leukocytes present in the
developing CL of several species—revised by Shirasuna et al.
[50]). As mentioned before, VEGF is also chemotactic for
macrophages [28], cooperating with TNF on CL immune
cells infiltration.
(ii) Luteal Regression. In the mare, late CL conditioned media
treated with PGF2𝛼 reducedmitogenic activity of BAEC [15].
In another study, after luteolytic PGF2𝛼 in vivo treatment, the
expression of proangiogenic factors in the CL was reduced,
and antiangiogenic factors production increased [88]. Also,
after 12 h of induced luteal regression with PGF2𝛼, on day
10 of the luteal phase, signs of swelling and apoptosis in
equine luteal endothelial cells, as well as detachment from the
blood vessels, were observed [88]. Active caspase-3 was also
identified in large luteal cells and endothelial cells [74, 78].
In both steroidogenic and endothelial cells, the increase in
caspase-3 expression was on day 14 of the luteal phase or 36 h
after PGF2𝛼 administration [89]. Another important finding
is the relationship between the onset of caspase-3 expression
in endothelial cells on day 14 of luteal phase (or after luteolysis
induction) and the decrease inmRNA and protein expression
of VEGF in steroidogenic cells [81]. Nevertheless, in the
mare there is no evidence that luteal endothelial cell death
is the trigger for luteolysis, since death of endothelial cells is
temporarily associated with death of steroidogenic cells.
Regarding the immune-vascular interaction at the time of
luteolysis, as previously reported in equine CL, macrophages
population mainly increases in the late luteal phase [90].
Moreover, an influx of neutrophils was seen during sponta-
neous regression in hamsters CL [91]. Although neutrophils
have been largely associated with phagocytosis, their partici-
pation in luteolysis has been also ascribed to cytokines secre-
tion [91]. Hence, our recent work clearly stated the cytokines
role on angiogenesis downregulation in equine CL [84]. In
the late CL, a startling rise in antiangiogenic factors pro-
duction after TNF treatment shows the stage specific role of
this cytokine (Figure 5(a)) [84].This definitely indicates TNF
pleiotropy, suggesting that its modulation of angiogenic-
signaling pathways depends on the local microenvironment
and auto-, paracrine interactions with other factors.
As mentioned in Section 2.4, TNF deleterious action on
bovine endothelial cells appears to be supported by IFNG
[16]. In our work, the synergic action of these two cytokines
on equine CL angiogenesis was not considered. Nevertheless,
IFNGalonewas able to decrease angiogenic activity in the late
CL (Figure 5(a)), but no other changes were observed [84]. It
should be also indicated that in the cow IFNG was associated
with senescence and antiproliferative effects on specific luteal
endothelial cell types [74].
Another interesting finding by this team was the demon-
stration of the negative effect played by FASL on VEGF
protein expression (Figure 2). Our conclusions concerning
FASL role on equine CL regulation show its importance
besides the so-well characterized participation in structural
luteolysis and apoptosis [92]. Initially, we have characterized
FASL participation in luteal secretory impairment at the
luteolysis time [93]. Since luteolysis is a dynamic process,
we hypothesized that FASL could play a role in angiogenesis
regulation. This cytokine is known to diminish angiogenesis
in different organs [94]. Also in the mare, we have shown
FASL specific downregulation of VEGF in the CL (Figure 2),
which may trigger angioregression.
We have also demonstrated that the cytokine association
TNF + IFNG + FASL decreases VEGF protein expression in
mid CL cells (Figure 2). In addition, cytokines association
adequately restricted angiogenesis, after (i) increasing TSP1
and CD36 mRNA level, (ii) decreasing VGEFR2 mRNA
level, and (iii) reducing BAEC proliferation in the late CL
(Figure 5). When all the cytokines were tested together
(TNF + IFNG + FASL), angiogenesis restriction was very
effective in late CL cells (reduction of BAEC viability—
Figure 5(a)). In late CL isolated cells, both TSP1 and CD36
mRNA levels were increased, while VEGFR2 was reduced
(Figure 5(b)). Although no changes were seen inmRNA level,
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the same cytokine combination also reduced VEGF protein
expression in mid CL cells (Figure 2).
The proteomic profile of these three cytokines (TNF,
IFNG, and FASL) show that the increase in their expression
[69, 82], and especially their synergic action, might be
associated with functional luteolysis and consequently with
angiogenesis downregulation (Figure 4(b)). Their combined
action on angiogenesis regression was also demonstrated in
the cow [16]. Thus, a temporal association between PGF2𝛼,
cytokines (TNF, IFNG, and FASL) increased expression, and
VEGF reduced expressionmay be amajor factor determining
angioregression in the equine CL (Figure 4(b)).
4. Conclusion
A subnormal CL from the immediate previous estrous cycle
will not prepare the uterus optimally for that gestation,
ending in abortion. Despite the seriousness of this problem,
the physiologic relevance of most studies on ovarian function
in woman is questionable, since they are based on knowledge
generated from abnormal tissue or granulosa cells collected
from in vitro fertilization in women subjected to exogenous
supraphysiological doses of gonadotropins [10]. Therefore,
several investigators have proposed that tissues of female
reproductive organs could serve as a model to study tissue
growth/regression and angiogenesis in general [13]. More-
over, proximities on ovarian physiology between mares and
women have been recently recognized [9]. Indeed, demon-
strated similarities between those species in the dynamics
of follicles during the interovulatory interval and during the
ovulatory follicular wave endow the equine ovary with the
best experimental model for studying ovarian function reg-
ulation [9]. Thus, we expect that produced data on ovarian
angiogenesis modulation in the mare will significantly con-
tribute for a better knowledge on the molecular mechanisms
regulating luteal vascular growth and regression. With a
short-term goal of a supportive application on assisted repro-
ductive technologies, generated insights are likely to con-
tribute for fertility improvement. Moreover, angiogenesis
in general is better elucidated, with special impact on vascular
diseases and tumorigenesis [3].
Many of the studies here cited represent amilestone in the
depiction of this complex process of angiogenesis in the CL. It
is now well established how crucial the interactions between
different luteal cellular departments are. To be precise,
immune cells, through their secreted cytokines, target gene
expression and cell viability of both endothelial and steroido-
genic luteal cells. This is a tight interaction where cytokines,
through their auto-, paracrine actions, are seen as the main
players. Hence, immune-vascular cross-talk was shown to
be determinant for both luteal establishment and regression.
Understanding themolecular regulation of these interactions
will contribute for a better knowledge on angiogenesis regu-
lation in general and luteal function in particular.
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